ddr

DDR-TRK-1, a selective discoid domain receptor 1 (DDR1) inhibitor, exhibits an IC50 value of 9.4 nM and also inhibits the TRK family.

DDR inhibitor is a potent discidin domain receptor (DDR) inhibitor. The IC50 of DDR2 is 3.3 nM, and DDR1 has 53% inhibition at 1.5 nM.

DDR1-IN-1 is an effective and specific DDR1 receptor tyrosine kinase inhibitor (IC50: 105 nM), about 3-fold selectivity over DDR2.

DDR1-IN-4 (Compound 2.45) is a highly potent inhibitor that selectively targets Discoidin Domain Receptor 1 (DDR1) autophosphorylation, demonstrating exceptional efficacy with IC50 values of 29 nM for DDR1 and 1.9 μM for DDR2.

DDR1-IN-2 (DDR1 inhibitor 7rh) (DDR1 inhibitor 7rh) is a potent, selective, ATP-competitive Discoidin domain receptor 1 (DDR1) inhibitor (IC50: 6.8 nM in cell-free kinase assays).

DDR2-IN-1 (Compound 129) is recognized as a highly effective DDR2 inhibitor, displaying an IC50 value of 26 nM. It is a suitable choice for conducting osteoarthritis research.

DDR1-IN-6 is a potent and selective inhibitor of Discoidin Domain Receptor family member 1 (DDR1), exhibiting remarkable inhibitory activity at an IC50 of 9.72 nM. It effectively suppresses the auto-phosphorylation of DDR1b (Y513) with an IC50 value of 9.7 nM. Furthermore, DDR1-IN-6 displays strong anti-cancer activity.

DDR1-IN-5 is a potent and selective inhibitor of the Discoidin Domain Receptor family, member 1 (DDR1). It effectively inhibits the phosphorylation of DDR1b (Y513) with an IC 50 value of 4.1 nM. Furthermore, DDR1-IN-5 demonstrates remarkable anti-cancer activity. Its inhibitory potency against DDR1 (IC 50 = 7.36 nM) makes it a promising compound for targeted therapy in cancer treatment.

WRG-28 is a potent and selective, allosteric discoidin domain receptor 2 (ddr2) inhibitor(IC50 : 230 nM)

Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib electively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing the constitutively activated c-Met protein.

Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.

VU6015929 is an inhibitor of active dual discoidin domain receptor 1/2 (DDR1/2)( IC50s of 4.67 nM and 7.39 nM, respectively).

5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone (DDR) is an anticancer agent that can be extracted from indigo. DDR inhibits the PI3K/AKT and NF-кB pathways, reducing the invasion and migration of cancer cells and exhibiting anticancer properties.

FGFR1/DDR2 inhibitor 1 is an inhibitor of discoidin domain receptor 2 (DDR2) and fibroblast growth factor receptor 1 (FGFR1), with IC50 values of 31.1 nM, 108.4 nM, and 3.2 nM for FGFR1, KG-1, and DDR2, respectively.

S 16020-2 is an olivacine derivative, and DNA topoisomerase II inhibitor endowed with a remarkable antitumor activity against various experimental tumors.

DDR Inhibitor 2 (compound 5a) is a potent inhibitor of the discoidin domain receptor (DDR) with an IC50 value of 0.125 μM, and it is applicable in fibrotic disease research.

DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, exhibiting IC50 values of 0.045 μM and 0.126 μM, respectively, and possesses antitumor activity.

DDR1-IN-1 dihydrochloride is a selective and potent inhibitor of the DDR1 receptor tyrosine kinase, exhibiting an IC50 of 105 nM, and it demonstrates fourfold reduced potency against DDR2, with an IC50 of 413 nM.

DDR1/2 Inhibitor-2 (Example 31) serves as an inhibitor of DDR1/DDR2, exhibiting IC50 values below 100 nM. It is applicable in cancer and fibrotic disease research [1].

Anti-DDR1/CD167a Antibody is a human-derived antibody expressed in CHO cells, targeting DDR1/CD167a. It features a muIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

DDR-TRK-1N is a negative control for DDR-TRK-1.

DDR1/2 inhibitor-3 (5n) is an inhibitor of DDR1/2, with IC50 values of 9.4 nM and 20.4 nM, respectively. It is applicable in anti-inflammatory research.

DDR1-IN-10 (compound 7q) is an inhibitor of DDR1. It is applicable in research related to pancreatic cancer, non-small cell lung cancer, and gastric cancer.

PROTACDDR1 degrader-1 is a PROTAC degrader specifically targeting DDR1.